Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules. Since beginning operations in 2017, Lundquist has supported Idorsia in defining and communicating its sustainability priorities.
In 2022, Idorsia launched its first commercially available product. Idorsia has always prioritised sustainability, so while the first therapies approached the final phases before reaching the market, the company required a more structured approach to sustainability disclosure.
Throughout 2021 and 2022, Lundquist supported Idorsia in defining sustainability KPIs, engaging data owners and collecting data in line with GRI guidelines. Following the collection of data, Lundquist put together the first drafts of the disclosures, organized by material topic in dedicated info sheets.
In February 2023, Idorsia published 12 info sheets, one for each material topic. Each info sheet includes the company’s management approach and a series of topic-specific disclosures. Not only has the exercise strengthened the company’s corporate transparency, it has also allowed internal stakeholders to become more engaged and proactive in sustainability topics. These topics will become increasingly more important as the company grows and is subject to more stringent regulations.